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Introduction
CBS domains were originally identified as sequence
motifs of approximately 60 amino acids that occur in
CBS and several other proteins, in all organisms from
archaea to humans (1). Although their functions were
unknown, their importance was emphasized by find-
ings that point mutations within them cause several
hereditary diseases in humans. These include (with the
protein/gene affected in parentheses): homocystinuria
(cystathionine β-synthase [ref. 2]); retinitis pigmentosa
(IMP dehydrogenase-1 [refs. 3, 4]); congenital myoto-
nia, idiopathic generalized epilepsy, hypercalciuric
nephrolithiasis, and classic Bartter syndrome (chloride
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CBS domains are defined as sequence motifs that occur in several different proteins in all kingdoms
of life. Although thought to be regulatory, their exact functions have been unknown. However, their
importance was underlined by findings that mutations in conserved residues within them cause a
variety of human hereditary diseases, including (with the gene mutated in parentheses): Wolff-Parkin-
son-White syndrome (γ2 subunit of AMP-activated protein kinase); retinitis pigmentosa (IMP dehy-
drogenase-1); congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis,
and classic Bartter syndrome (CLC chloride channel family members); and homocystinuria (cys-
tathionine β-synthase). AMP-activated protein kinase is a sensor of cellular energy status that is acti-
vated by AMP and inhibited by ATP, but the location of the regulatory nucleotide-binding sites
(which are prime targets for drugs to treat obesity and diabetes) was not characterized. We now show
that tandem pairs of CBS domains from AMP-activated protein kinase, IMP dehydrogenase-2, the
chloride channel CLC2, and cystathionine β-synthase bind AMP, ATP, or S-adenosyl methionine,while
mutations that cause hereditary diseases impair this binding. This shows that tandem pairs of CBS
domains act, in most cases, as sensors of cellular energy status and, as such, represent a newly iden-
tified class of binding domain for adenosine derivatives.
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channels CLC1, CLC2, CLC5, and CLCKB, respective-
ly [refs. 5–8]); and Wolff-Parkinson-White syndrome
(WPWS) (γ2 subunit of AMP-activated protein kinase
[refs. 9–12]). Although not yet reported in humans,
mutations in the CBS domains of the AMP-activated
protein kinase (AMPK) γ3 subunit cause an abnormal-
ly high glycogen content in skeletal muscle of pigs (13).
AMPK is a cellular energy sensor that is activated by
AMP and inhibited by high concentrations of ATP (14).
Once activated by cellular stresses that cause ATP deple-
tion, the kinase switches on catabolic pathways that
generate ATP and switches off ATP-consuming process-
es. As well as maintaining energy balance at the cellular
level, it is now becoming clear that AMPK plays an
important role in regulating whole-body energy storage
and expenditure. The drug 5-aminoimidazole-4-car-
boxamide (AICA) riboside, which activates AMPK, alle-
viates metabolic defects of type 2 diabetes and the meta-
bolic syndrome in animal models (15–18). The kinase is
activated by exercise in muscle (19), stimulating glucose
and fatty acid oxidation (20), and may be partly respon-
sible for the protective effects of exercise in the develop-
ment of obesity and type 2 diabetes. It is also activated
by the antidiabetic drugs metformin and rosiglitazone
(21–23), and by the adipocyte-derived hormones leptin
and adiponectin (24, 25). AMPK activators are now rec-
ognized as prime candidates for new drugs to treat type
See the related Commentary beginning on page 182.
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2 diabetes, obesity, and the metabolic syndrome (26, 27),
but the locations of the regulatory AMP- and ATP-bind-
ing sites (the most likely binding sites for activators)
have not been characterized.
AMPK exists as heterotrimeric complexes comprising
catalytic α subunits and regulatory β and γ subunits (14).
CBS domains invariably occur as tandem pairs, but the
three γ subunit isoforms of AMPK, and their homologues
in lower eukaryotes, are unique among eukaryotic pro-
teins in having four tandem domains, although other
examples are found in archaeal genomes. We have previ-
ously shown, using a photolabile AMP analogue, that the
γ subunits are involved in binding of the nucleotide (28).
Since the four CBS domains are the only regions con-
served between the three γ isoforms, we hypothesized that
they form the allosteric nucleotide-binding sites. In this
paper we have examined the hypothesis that pairs of CBS
domains form binding sites for adenosine-containing lig-
ands, and that this is disrupted by disease mutations.
Methods
DNA cloning and expression. PCDNA plasmids encoding
rat γ1 (29) and human γ2 and γ3 (28) were used as tem-
plates for PCR. DNAs encoding all four CBS domains
(CBS1-4) from γ1 (residues 42–324), γ2 (residues
274–569), and γ3 (residues 197–479), and the N-termi-
nal domain pair from γ2 (CBS1-2, residues 274–410) or
the C-terminal domain pair from γ2 (CBS3-4, residues
430–556), were amplified using the Pfu Turbo PCR kit
(Stratagene, La Jolla, California, USA). The primers were
designed to amplify DNA encoding the designated
amino acids but also contained 5′-BamHI and 3′-XhoI
ends. The PCR products were cloned into pGEX-KG
using those restriction sites. For IMP dehydrogenase-2
(IMPDH2), DNAs encoding residues 112–232 or the
full-length protein (residues 1–514) were amplified
using human liver cDNA (BD Biosciences Clontech,
Oxford, United Kingdom) as template, and cloned into
pHAT20 (BD Biosciences Clontech) using 5′-AgeI and
3′-KpnI sites added to the primers. For the other con-
structs, DNAs encoding residues 582–840 of CLC2, or
416–551 of cystathionine β-synthase, were amplified
using human liver cDNA as template, and cloned into
pGEX-KG as described above. All mutations were creat-
ed using the QuikChange Site-Directed Mutagenesis
system (Stratagene).
Bacterial expression and purification of proteins. Luria-
Bertani medium (1 liter) containing ampicillin (50
µg/µl) was inoculated with overnight cultures (10 ml) of
Escherichia coli BL21 (DE3) containing the appropriate
construct. Cultures were grown at 37°C until the
absorbance at 600 nm reached 0.4, after which isopropyl
thiogalactoside (1 mM) was added to induce expression.
Cells were recovered by centrifugation 3 hours later, and
cell pellets were resuspended in 20 ml of PBS, pH 7.4,
containing 1 mM EDTA, 5 mM DTT, 1 mg/ml lysozyme,
and Complete Protease Inhibitor Cocktail (Roche Diag-
nostics, Lewes, United Kingdom). Following incubation
on ice for 30 minutes, the cells were lysed in Sarkosyl
(1.5% vol/vol), and cellular debris were removed by cen-
trifugation at 300,000 g (4°C, 1 hour). Triton X-100 (2%
vol/vol) was added, and the lysate was applied to a 5-ml
glutathione-Sepharose column pre-equilibrated with
PBS. The column was washed with 5 volumes of PBS
containing 1 M NaCl, followed by 5 volumes of PBS
without NaCl. Protein was eluted with 20 ml of PBS, pH
7.4, containing 20 mM reduced glutathione. Protein-
containing fractions were dialyzed against Tris-buffered
saline (TBS), pH 7.4, and concentrated using centrifugal
ultrafiltration (Biomax-10K; Millipore Corp., Bedford,
Massachusetts, USA). The IMPDH2 constructs were
polyhistidine-tagged and were purified on chelating
Sepharose (Pharmacia, Chalfont St. Giles, United King-
dom) charged with 50 mM CoCl2 according to the man-
ufacturer’s instructions. The molar concentrations of
proteins were determined from their absorbance at 280
nm, and extinction coefficients were calculated from the
amino acid sequence. All proteins were homogeneous by
SDS-PAGE, except that for the CBS1-2, CBS3-4, and
CLC2 constructs there was a minor degree of proteolyt-
ic degradation (<10%). In those cases, the concentrations
were corrected by densitometric estimation of the pro-
portion of full-length protein.
Expression of AMPK heterotrimers in CCL13 cells and kinase
assays. CCL13 cells from American Type Culture Collec-
tion (Manassas, Virginia, USA) were grown in DMEM
with GlutaMax-1 (GIBCO catalog no. 61965-026; Life
Technologies, Paisley, United Kingdom) plus FBS (10%
vol/vol). PCDNA plasmids (28–30) encoding myc-
tagged α1, β1, and γ1, γ2, or γ3 were purified using
HiSpeed Plasmid Maxi kits (QIAGEN, Crawley, United
Kingdom), and expressed by transient transfection
using SuperFect (QIAGEN Inc.) in CCL13 cells (30).
After 48 hours, the cells, 80–90% of which were conflu-
ent by this time, were subjected to “rapid lysis,” and the
lysates were immunoprecipitated using anti-myc anti-
body and assayed as described previously (31). Results
are means ± SD from triplicate transfections. “Slow
lysis” of CCL13 cells was as described by Stein et al. (32).
AMPK activities were corrected for minor differences in
expression levels by analysis of cell lysates by SDS-PAGE
and probing of blots with anti–AMPK-α1 antibody
(0.06 µg/ml) directly conjugated to IRDye 800 (Molec-
ular Probes Inc., Eugene, Oregon, USA) in TBS-Tween
(10 mM Tris/HCl, pH 7.4, 0.5 M NaCl, Tween-20 [1%
wt/vol]) plus nonfat milk powder (1% wt/vol). After
washing (six times for 5 minutes in TBS-Tween and
once for 5 minutes in PBS), the remaining dye on the
membrane was quantified using an Odyssey IR imager
(LI-COR Biosciences, Cambridge, United Kingdom).
Ligand-binding assays. The method to determine ligand
binding was based on that of Janosik et al. (33). Various
concentrations of [14C]AMP (2 MBq/µmol), [14C]S-
adenosyl methionine (2 MBq/µmol), or [γ-32P]ATP (5
MBq/µmol) were incubated with glutathione-S-trans-
ferase–CBS domain fusions (1 µM for WT, up to 20 µM
for some mutants) for 10 minutes at 25°C in a 20-µl
total volume in TBS (50 mM Tris/HCl, pH 7.4, 150 mM
 
276 The Journal of Clinical Investigation | January 2004 | Volume 113 | Number 2
NaCl). To stop the reactions, 10 µl of the reaction mix-
ture was spotted onto a Millipore MF Filter Membrane
disc (2.5 cm; Millipore Corp.), rapidly filtered under
high vacuum (0.13 mbar, <1 second), and washed with
1 ml of ice-cold TBS. Radioactivity was determined on
the filters by scintillation counting. Nonspecific bind-
ing (typically <200 disintegrations per minute (dpm),
compared with specific binding of >4,000 dpm) was
determined by control assays with glutathione-S-trans-
ferase (GST) and was subtracted. For ATP binding, 5
mM MgCl2 was routinely included; it was omitted for
studies of AMP binding, although MgCl2 did not affect
the binding of either nucleotide. Data were fitted to the
binding models given in the text, using GraphPad Prism
3 (GraphPad Software Inc., San Diego, California, USA).
Estimates of resulting parameters, ± SE, are given in the
text and Table 1, and the curves shown in the figures are
theoretical curves obtained using those estimates.
Enzymatic assay of IMPDH2. We assayed IMPDH2 by
following the increase in absorbance at 340 nm due to
formation of NADH in a BMG FLUOstar OPTIMA
plate reader (BMG Lab Technologies, Aylesbury, Unit-
ed Kingdom) at 30°C in plate mode. The assay buffer
contained 50 mM Tris/HCl, 100 mM KCl, 1 mM DTT,
3 mM EDTA, and 5 mM MgCl2. Where ATP was added,
additional MgCl2 was added to maintain a constant 
5-mM excess of MgCl2 over ATP. The total volume was
200 µl, and the reaction was started by addition of IMP.
Results
The N-terminal and C-terminal CBS domain pairs from
AMPK-γ2 bind one molecule of AMP or ATP. The crystal
structure of a bacterial IMPDH shows that the tandem
pair of CBS domains are intimately associated via
hydrophobic interactions between homologous β
sheets composed of three strands from one domain
and one from the other (34), making it very unlikely
that single domains would be stable. We therefore
cloned DNA from human AMPK-γ2 encoding either all
four domains (CBS1-4), or the N-terminal pair (CBS1-2)
or the C-terminal pair (CBS3-4). All three constructs
were expressed as GST fusions in bacteria and were
purified on glutathione-Sepharose as soluble proteins
of the expected sizes in good yield. Binding of AMP was
assessed using [14C]AMP and a rapid-filtration method.
Initial fitting of the data using the WT CBS1-2 fusion
showed that the maximal binding was very close to 1
mole (0.95 ± 0.05) per mole of protein, so data were
subsequently fitted to a single-site binding model (Fig-
ure 1a), yielding a dissociation constant (Kd) of 53 µM.
We also used site-directed mutagenesis to create four
of the mutations in CBS1-2 that cause WPWS, i.e.,
R302Q, H383R and T400N, and Lins (which inserts a
leucine residue in the linker between CBS1 and CBS2).
All mutants still bound one molecule of AMP, but the
Kd values for R302Q, T400N, and H383R were increased
six-, ten-, and 28-fold, respectively, relative to that for
Table 1
Binding parameters for AMP and ATP, measured with various constructs of AMPK, IMPDH2, and CLC2
Protein Construct nA KdB or B0.5 AMP (µM) h AMP KdB or B0.5 ATP (µM) h ATP
AMPK-γ2 CBS1-2 (WT) 1 53 ± 5 - 175 ± 20 -
CBS1-2 (R302Q) 1 303 ± 42 - 468 ± 86 -
CBS1-2 (Lins) 1 63 ± 7 - 202 ± 22 -
CBS1-2 (H383R) 1 1,500 ± 210 - 1,570 ± 140 -
CBS1-2 (T400N) 1 556 ± 56 - 952 ± 55 -
CBS3-4 (WT) 1 104 ± 10 - 403 ± 16 -
CBS3-4 (R531G) 1 1,570 ± 110 - 2,050 ± 150 -
CBS1-4 (WT) 2 61 ± 2 2.2 ± 0.1 257 ± 14 2.2 ± 0.2
CBS1-4 (R302Q) 2 158 ± 9 1.9 ± 0.2 193 ± 25 1.3 ± 0.2
CBS1-4 (Lins) 2 130 ± 4 1.8 ± 0.1 335 ± 28 1.8 ± 0.2
CBS1-4 (H383R) 2 725 ± 36 1.8 ± 0.2 1,470 ± 55 2.4 ± 0.2
CBS1-4 (T400N) 2 1,360 ± 47 1.8 ± 0.1 2,000 ± 160 1.7 ± 0.2
CBS1-4 (R531G) 2 2,800 ± 220 1.6 ± 0.2 2,550 ± 230 2.7 ± 0.5
AMPK-γ1 CBS1-4 2 20 ± 1 1.6 ± 0.2 119 ± 7 1.9 ± 0.2
AMPK-γ3 CBS1-4 2 125 ± 11 2.2 ± 0.1 989 ± 58 1.5 ± 0.1
IMPDH2 CBS1-2 (WT) 1 437 ± 53 - 54 ± 6 -
CBS1-2 (R224P) 1 - - 450 ± 36 -
Tetramer (WT) 4 - - 770 ± 50 1.7 ± 0.2
Tetramer (R224P) 4 - - 64,000 ± 5,000 0.9 ± 0.1
CLC2 CBS1-2 (WT) 1 1,060 ± 80 -
CBS1-2 (G715E) 1 10,400 ± 1,300 -
1 14,300 ± 550 -
CBS CBS1-2 (WT) 1 34 ± 2C
D444N 1 510 ± 70C
An = number of binding sites assumed per protein molecule. BWhere a single binding site is assumed, the data were fitted to a simple binding equation,
Y = L/(Kd + L), where Y is fractional saturation and L is ligand concentration, and the value given in this column is Kd; where more than one binding site
is assumed, the data were fitted to the Hill equation, Y = Lh/(B0.5h + Lh), where h is the Hill coefficient and B0.5 is the ligand concentration giving half-max-
imal binding, and the value given in this column is B0.5. CThese are Kd values for S-adenosyl methionine, not AMP.
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the WT (Figure 1a and Table 1). The Kd for Lins was not
significantly different from that for the WT.
Since high concentrations of ATP antagonize activa-
tion of AMPK by AMP (35), we suspected that the
CBS1-2 proteins would also bind ATP. This was indeed
the case, and for the WT the data could be fitted to a
single-site binding model with a Kd 3.3-fold higher than
that for AMP. All of the mutants still bound ATP, but
the Kd values were increased in the same rank order as
for AMP binding, albeit to a lesser extent. For R302Q,
T400N, and H383R, the increases were three-, five-, and
ninefold, respectively, while Lins was again not signifi-
cantly different from the WT (Figure 1b and Table 1).
High concentrations of ATP completely displaced
binding of AMP from the WT (Figure 2), showing that
binding of the two nucleotides is mutually exclusive.
We also measured the apparent Kd for AMP of the WT
CBS1-2 protein in the presence of four different con-
centrations of ATP and fitted the results to the equa-
tion: apparent Kd = KdAMP(1 + [ATP]/KdATP). This yield-
ed estimates for KdAMP and KdATP of 51 and 180 µM,
respectively, very close to the estimates obtained by
direct binding measurements (53 and 175 µM).
The CBS3-4 fusion protein bound a single molecule
of AMP with a Kd of 104 µM. We also created a single
point mutation in CBS3-4 that causes WPWS when
present in intact γ2, i.e., R531G. The mutant still
bound AMP, but the Kd increased 15-fold (Figure 1c
and Table 1). The WT also bound ATP with a Kd four-
fold higher than that for AMP, while the Kd for ATP was
increased fivefold relative to the WT in the R531G
mutant (Figure 1d and Table 1).
The four tandem CBS domains from AMPK-γ2 bind two
molecules of AMP or ATP with positive cooperativity. Since
the CBS1-2 and the CBS3-4 fusion proteins from γ2
each bound one molecule of AMP or ATP, we expect-
ed that the CBS1-4 construct would bind two, which
was indeed the case. The best fits were obtained using
a Hill plot model with two identical, interacting sites:
bound = 2 × [AMP]h/(B0.5h + [AMP]h), where h is the
Hill coefficient and B0.5 is the concentration giving
half-maximal binding (Figure 3a and Table 1). For the
WT γ2 construct, this yielded a B0.5 for AMP of 61 µM.
The Hill coefficient was close to 2, indicating that the
two sites bind AMP with strong positive cooperativi-
ty, i.e., that once AMP is bound at the first site the
affinity at the second site increases so that it fills
almost immediately. Similar results were obtained for
the binding of ATP (Figure 3b and Table 1), which
yielded a B0.5 more than fourfold higher than that for
AMP, consistent with the finding that both CBS1-2
and CBS3-4 bound ATP with lower affinity than AMP.
All WPWS mutants still bound two molecules of
AMP, but the B0.5 values were markedly increased (Fig-
ure 3a and Table 1). For Lins, R302Q, H383R, T400N,
and R531G, the increases in B0.5 were 2.1-fold, 2.6-
fold, 12-fold, 22-fold, and 46-fold, respectively. All
Figure 1
Binding of AMP (a and c) or ATP (b and d) by
the CBS1-2 construct (a and b) or the CBS3-4
construct (c and d). The fusion proteins were
either the WT (open circles) or one of five
point mutants (R302Q, filled circles; Lins,
open squares; H383R, filled squares; T400N,
open triangles; R531G, filled triangles). Data
were fitted to a single-site binding model:
bound = [nucleotide]/(Kd + [nucleotide]). The
curves are theoretical curves obtained using
the Kd values shown in Table 1.
Figure 2
Displacement of AMP from the CBS1-2 construct by ATP. A fixed
concentration of [14C]AMP (180 µM) was incubated with the
CBS1-2 construct in the presence of increasing concentrations of
ATP. Data were fitted to the binding model: bound = AMP/[AMP
+ KdAMP(1 + [ATP]/KdATP)].
278 The Journal of Clinical Investigation | January 2004 | Volume 113 | Number 2
mutants also bound two molecules of ATP, but with
changes in B0.5 and/or Hill coefficient (Figure 3b and
Table 1), except for the Lins mutant, which was not
significantly different from the WT.
Binding of AMP and ATP to the four tandem CBS domains
from AMPK-γ1 and -γ3. We also made CBS1-4 fusion pro-
teins from the γ1 and γ3 isoforms. These also bound two
molecules of AMP and ATP with positive cooperativity,
but with B0.5 values that were significantly lower (γ1) or
higher (γ3) than for γ2 (Table 1, Figure 3, c and d). For
the constructs from γ1, γ2, and γ3, the B0.5 values for
AMP were 20, 53, and 125 µm, respectively.
Effects of WPWS mutations on activation of AMPK het-
erotrimers by AMP. While the results in the previous sec-
tion showed that isolated CBS domain pairs bind AMP
and ATP, they did not conclusively prove that these
domains form the regulatory nucleotide binding sites
in the heterotrimeric AMPK complex. To address this,
we expressed recombinant α1β1γ2 heterotrimers in
WT and mutated forms in CCL13 cells, purified them
by immunoprecipitation via myc epitope tags on the α
subunit, and assayed at various AMP concentrations.
CCL13 cells (a human cell line now thought to be a
variant of HeLa cells) were used because they have a
high transfection efficiency and a low endogenous
AMPK activity. Figure 4a shows that, for the Lins,
R302Q, H383R, T400N, and R531G mutations, the A0.5
values (concentration causing half-maximal activation)
for AMP increased in the same order in which these
mutations increased the B0.5 for binding of AMP to the
isolated CBS1-4 constructs, i.e., WT (7 ± 3 µM) ≈ Lins 
(9 ± 4 µM) < R302Q (23 ± 6 µM) < H383R (51 ± 40 µM)
< T400N (95 ± 32 µM) < R531G (>100 µM). The A0.5
Figure 3
(a and b) Binding of AMP (a) and ATP (b) to the
GST–CBS1-4 fusion protein from γ2 and WPWS
mutants. (c and d) Binding of AMP (c) and ATP (d)
by the GST–CBS1-4 fusion proteins from γ1, γ2, and
γ3. The methodology was as for Figure 1, except that
data were fitted to a two-site Hill plot model:
bound = 2 × [nucleotide]h/(B0.5h + [nucleotide]h).
Figure 4
(a) Activation of recombinant α1β1γ2 heterotrimers, with or without
WPWS mutations, by AMP. (b) Activation of recombinant α1β1γ1,
α1β1γ2, and α1β1γ3 heterotrimers by AMP. (c) Activation of α1β1γ2
heterotrimers, with or without WPWS mutations, by slow versus rapid
lysis. Plasmids expressing myc-tagged α1 and β1 plus one of the sub-
units γ1, γ2 (with or without WPWS mutations), and γ3 were
expressed in CCL13 cells, and the recombinant complexes were
immunoprecipitated using anti-myc antibodies. AMPK activity was
then determined at various concentrations of AMP. In a and b, the
cells were harvested by slow lysis to elicit maximal phosphorylation
(32); in c, the cells were harvested by rapid or slow lysis and the assays
were conducted at 200 µM AMP. Results are means ± SE for dupli-
cate immunoprecipitations.
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values for the heterotrimers were all around tenfold
lower than the B0.5 values for the isolated CBS1-4 con-
structs, indicating that the presence of the α and/or β
subunits increased the affinity for AMP. It was not pos-
sible to conduct assays above 100 µM AMP, because at
these concentrations the nucleotide inhibits the activ-
ity by competing with ATP at the kinase domain on the
α subunit. For this reason, the estimates of A0.5 for the
H383R and T400N mutants are less accurate than the
others, while no value could be obtained for the R531G
mutant. The latter appeared to have a slightly elevated
basal activity in the absence of AMP and was actually
inhibited by addition of AMP. With some mutants, the
maximal activation also appeared to be affected. For
example, the R302Q mutant was only stimulated three-
fold by AMP, whereas the WT was stimulated sixfold.
Effects of γ isoform on activation of AMPK heterotrimers by
AMP. Figure 4b shows that when the activations of the
WT α1β1γ1, α1β1γ2, and α1β1γ3 heterotrimers were
compared using the same methodology, they differed
in the degree of stimulation by AMP rather than in the
A0.5 for AMP. The α1β1γ1, α1β1γ2, and α1β1γ3 het-
erotrimers were stimulated 3.3-, 7.0-, and 1.5-fold by
AMP, but the A0.5 values were similar (13 ± 2, 12 ± 3,
and 2 ± 2 µM, respectively). The value of A0.5 for α1β1γ3
is approximate, because of the very small degree of
stimulation by AMP with that isoform.
Mutations in γ2 do not cause constitutive activation of AMPK.
It has previously been claimed that mutations that are
associated with WPWS cause constitutive activation of
AMPK (12, 36). To address this, we examined the activa-
tion of expressed AMPK in CCL13 cells by slow lysis as
opposed to rapid lysis. Slow lysis involves harvesting the
cells by scraping them off and centrifuging them prior to
resuspension in homogenization medium and activates
AMPK by a combination of mechanical stress, hypoxia,
and/or glucose deprivation. Rapid lysis involves pouring
off the medium and lysing the cells in situ on the culture
dish using ice-cold lysis buffer, and this better preserves
the physiological phosphorylation status of AMPK. Fig-
ure 4c shows that the stress of slow lysis significantly acti-
vated the α1β1γ1, α1β1γ2, and α1β1γ3 heterotrimers,
although the degree of activation was lowest with the
α1β1γ3 complex. All of the γ2 mutants were also activat-
ed, although the degree of activation of the R302Q,
H383R, T400N, and R531G mutants was significantly
lower than that of the WT and the Lins mutant. There
was no evidence for constitutive activation of any of the
mutants when the cells were harvested by rapid lysis.
The CBS domains from IMPDH bind ATP, and this is
impaired by a mutation that causes retinitis pigmentosa. To
examine whether binding of adenine nucleotides is a
more general function for CBS domains, we also stud-
ied IMPDH. Retinitis pigmentosa can be caused by an
R224P mutation in the second CBS domain of the
IMPDH1 isoform (4). However, IMPDH2 is 84% iden-
tical in amino acid sequence with IMPDH1, and the
arginine mutated in retinitis pigmentosa is conserved.
Because cDNA was more readily available for IMPDH2,
we cloned DNA encoding the single pair of CBS
domains from that isoform, created an R224P muta-
tion, and expressed the WT and the mutant as polyhis-
tidine-tagged proteins in E. coli. The WT fusion protein
bound one molecule of ATP with a Kd of 54 µM, while
in the mutant the Kd increased more than eightfold
(Figure 5a and Table 1). Using displacement of bound
ATP as the assay, the WT protein also bound AMP or
GMP, but only at supraphysiological concentrations
(Kd = 440 and 5,760 µM, respectively).
We also cloned and expressed full-length IMPDH2
and examined the binding of ATP (Figure 5b). Interest-
ingly, this protein (which is a tetramer) bound ATP with
a B0.5 of 0.76 mM, 14-fold higher than the Kd for the iso-
lated CBS domains, and much closer to the physiologi-
cal range of ATP concentrations. An ultraviolet absorp-
tion spectrum of the purified protein showed that it did
not contain any endogenous bound nucleotide. The
binding of ATP to full-length IMPDH2, but not to the
isolated CBS domains, also displayed positive coopera-
Figure 5
(a and b) Binding of ATP by GST fusions of the isolated CBS domain
pair (residues 112–232) (a) and full-length IMPDH2 (residues 1–514)
(b). (c) Activity of full-length IMPDH2 as a function of ATP concentra-
tion. Results were obtained for both the WT sequence and an R224P
mutation. Data in a and b were fitted to a single-site binding model as
for Figure 1. Data in c were fitted to the model: activity = basal + {[(stim-
ulation × basal) – basal] × [ATP]h}/(A0.5h + [ATP]h).
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tivity, with a Hill coefficient of 1.7. ATP binding by the
full-length tetramer was also drastically affected by the
R224P mutation, with a more than 80-fold increase in
B0.5 (Figure 5b and Table 1).
ATP is an allosteric activator of IMPDH. Since we could
not find any published reports describing effects of ATP
on IMPDH activity, we assayed the recombinant enzyme
in the presence and absence of the nucleotide. Figure 5c
shows that ATP stimulated IMPDH activity more than
fourfold with a half-maximal effect at 0.44 ± 0.05 mM
and a Hill coefficient of 1.3 ± 0.1. This is close to the B0.5
and Hill coefficient obtained for ATP binding to the
tetramer. The effect of ATP was on Vmax, rather than on
the Km for the substrates IMP or NAD+ (not shown).
Even at the highest concentration used (2 mM), ATP
had no effect on the R224P mutant version of the full-
length tetramer (Figure 5c). This is consistent with the
insignificant level of binding of ATP to the tetramer at
this concentration (Figure 5b).
The CBS domain pair from the chloride channel CLC2 binds
ATP, and this is severely affected by pathogenic mutations. We
also cloned and expressed DNA encoding the CBS
domain pair from the chloride channel CLC2. Figure
6 shows that this construct bound one molecule of
ATP with a Kd of 1.06 ± 0.08 mM, while G715E and
G826D mutations were associated with ten- and 14-
fold increases in Kd, respectively.
The CBS domain pair from cystathionine β-synthase binds
S-adenosyl methionine, and this is affected by a homocystinuria
mutation. Finally, we cloned and expressed DNA encod-
ing the C-terminal CBS domain pair from the enzyme
cystathionine β-synthase. This yielded a preparation
that was homogeneous by SDS-PAGE and predomi-
nantly migrated as a monomer on native gel electro-
phoresis (not shown). This domain pair bound one
molecule of S-adenosyl methionine (SAM) with a Kd of
34 ± 2 µM, while the D444N mutation that causes
homocystinuria (2) increased the Kd for SAM 15-fold to
510 ± 70 µM (Figure 7).
Discussion
Overall, our results show that tandem pairs of CBS
domains form allosteric binding sites for adenosine
derivatives, i.e., AMP and ATP in the case of AMPK,
ATP in the cases of IMPDH and CLC2, and SAM in the
case of cystathionine β-synthase. Moreover, they show
that the many mutations in CBS domains that cause
human hereditary diseases invariably impair the bind-
ing of these regulatory adenosine derivatives. To our
knowledge, our findings represent not only the first
direct evidence as to the function of CBS domains, but
also the first description of the biochemical defect in
several human hereditary diseases where mutations
occur in these domains.
Our results strongly support the idea that the four
tandem pairs of CBS domains in the γ subunits of
AMPK provide two allosteric binding sites for AMP
and ATP in the heterotrimeric complex, one or both
of which are therefore targets for development of
drugs aimed at obesity and type 2 diabetes. The evi-
dence in favor of this may be summarized as follows:
(a) While the N-terminal and C-terminal pairs of CBS
domains from the γ2 subunit both bound one mole-
cule of AMP when expressed in and purified from
bacteria, the construct containing all four domains
bound two molecules of AMP. (b) Mutations that
caused an increase in the B0.5 for binding of AMP to
the CBS domains of γ2 also caused an increase in the
A0.5 for activation of recombinant α1β1γ2 complex-
es, with the same order of potency, i.e., B0.5 or A0.5 for
WT ≈ Lins < R302Q < H383R < T400N < R531G. (c)
ATP also bound to the bacterially expressed CBS
domains in a mutually exclusive manner with AMP,
albeit with lower affinity. This is consistent with the
fact that high concentrations of ATP inhibit allosteric
activation of AMPK in a manner that appears to be
competitive with AMP (35). Although mutually exclu-
sive binding to the bacterially expressed CBS domains
does not prove that AMP and ATP bind to the same
site, this is the simplest explanation that is also con-
Figure 7
Binding of SAM by a GST fusion of the isolated CBS domain pair
(residues 416–551) from cystathionine β-synthase, and binding of
SAM by a D444N mutation. Data were fitted to a single-site binding
model as for Figure 1.
Figure 6
Binding of ATP by a GST fusion of the isolated CBS domain pair
(residues 582–840) from CLC2, and binding of ATP by G715E and
G826D mutations. Data were fitted to a single-site binding model
as for Figure 1.
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sistent with our findings that the γ2 mutations
reduced the affinity for ATP in the same order in
which they reduced the affinity for AMP.
Our studies on AMP activation of heterotrimeric
AMPK complexes are in good agreement with those of
Daniel and Carling (37), who found that mutations
associated with WPWS exhibited defective activation
by AMP, with the effect on A0.5 increasing in the order
WT ≈ Lins ≈ R302Q < H383R (they did not study the
T400N mutant). Like we found, Daniel and Carling
found that the maximal stimulation by AMP was
reduced by the R302Q mutation, while with the
R531G mutant the stimulation by AMP was abolished
and the basal activity measured in the absence of AMP
was slightly higher. They suggested that the latter
might be because the inhibitory effect of ATP might
also be reduced with this mutant. This is supported by
our findings that the affinity of the R531G mutant for
ATP, when expressed in the context of either CBS3-4
or CBS1-4 (Table 1), was greatly reduced.
Neither our results nor those of Daniel and Carling
(37) support two previous claims (12, 36) that WPWS
mutations make AMPK complexes constitutively
active. When the cells were harvested by rapid lysis
(which much better preserves the physiological phos-
phorylation state of AMPK), none of the mutants
exhibited greater activity than the WT (Figure 4c).
When the cells were harvested by the slow-lysis pro-
cedure (which causes activation of AMPK due to
hypoxia, glucose deprivation, and/or mechanical
stress), the mutants that exhibited defective activa-
tion by AMP in vitro (R302Q, H383R, T400N, and
R531G) were all activated, although to a lower extent
than the WT. Of the two previous claims that the
mutations caused constitutive activation of AMPK,
both relied on indirect approaches. One involved
making a mutation equivalent to R302Q in the γ1
rather than the γ2 isoform (36), although naturally
occurring mutations in γ1 have not been reported.
The other involved making mutations equivalent to
T400N and N488I in the yeast γ subunit homologue,
Snf4, and analyzing two-hybrid interactions with
Snf1 (the α homologue) as a surrogate measure of
kinase activity (12). In fact, while both mutations did
appear to cause small (twofold) increases in the
Snf1/Snf4 interaction under basal conditions,
removal of glucose from the medium (known to acti-
vate the SNF1 complex [ref. 38]) appeared to cause
further large increases in interaction with both of the
mutants as well as with the WT. The use of the term
“constitutively active” to describe these Snf4 mutants
(12) is therefore misleading. Our results and those of
Daniel and Carling (37) suggest that while the
R531G mutant has a slightly elevated basal activity
(due perhaps to reduced binding of the inhibitor,
ATP), the major effect of the mutations is to reduce
activation of AMPK in response to stress.
Our results with IMPDH2 and CLC2 suggest that
sensing of cellular energy status by binding of ade-
nine nucleotides may be a general function of CBS
domain pairs, rather than being a function restricted
to AMPK. The CBS domain pairs from IMPDH2 also
bound AMP and GMP in vitro in addition to ATP,
but only ATP bound at physiologically relevant con-
centrations. IMPDHs catalyze the first step in purine
nucleotide biosynthesis that is committed to synthe-
sis of GMP rather than AMP. They are subject to feed-
back inhibition by GMP, but GMP did not bind with
high affinity to the CBS domains. Since inhibition by
GMP is competitive with the substrate, IMP (39), it is
more likely that feedback inhibition is due to bind-
ing of GMP to the catalytic site. It is interesting that,
while ATP bound to the isolated CBS domain pair
from IMPDH2 with a Kd in the low micromolar range
(54 µM) with no evidence for interaction between
sites, it bound to full-length enzyme with positive
cooperativity and a B0.5 (770 µM) that was 14-fold
higher and much closer to the physiological range of
ATP concentrations. The crystal structures of mam-
malian and bacterial IMPDH show that the enzyme
is a tetramer with the CBS domain pairs on the out-
side, with subunit contacts being made entirely by
the catalytic domains (34, 40). Our results suggest
that the CBS domain pairs in the tetramer are con-
strained in a conformation that has a lower affinity
for ATP than the isolated domains have, but that
binding of ATP to the first site causes a conforma-
tional change that is transmitted across the subunit
interface to increase the affinity of the remaining
CBS domain pairs.
Figure 8
Model of the N-terminal pair of CBS domains (CBS1 and CBS2) from
the γ2 subunit of AMPK. The picture is a view of a molecular-surface
representation made using the program GRASP (Department of Bio-
chemistry, Columbia University, New York, New York, USA) (51), with
CBS1 on the left. The model was made using MODELLER 6 (Depart-
ment of Biopharmaceutical Sciences, University of California San
Francisco, San Francisco, California, USA) (52) and was based on the
atomic coordinates of the CBS domain pair from a bacterial IMPDH
(Protein Data Bank code 1ZFJ) (34). Electrostatic potential at the sur-
face is depicted as red for negative and blue for positive. The approx-
imate positions of residues mutated in WPWS are shown. R302 and
H383 occupy equivalent positions in CBS1 and CBS2, respectively,
and are adjacent to each other in the model. Part of residue T400
projects into the hydrophobic cleft between the two domains.
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We were unable to find any previous reports that
IMPDH was activated by ATP, but our results now
show, for the first time to our knowledge, that the
nucleotide increases the Vmax of the enzyme more than
fourfold. The reasonably close correspondence between
the B0.5 for ATP binding (770 µM) and the A0.5 for ATP
activation (440 µM) of the tetramer, and the finding
that the R224P mutation in the second CBS domain
abolishes both binding of ATP and activation by ATP,
provide strong evidence that the allosteric activation is
due to binding of the nucleotide to the CBS domains.
We propose that this mechanism ensures that the syn-
thesis of guanine nucleotides only occurs when the
supply of ATP is sufficient, a mechanism that accom-
panies feedback inhibition by GMP. This is analogous
to the regulation of the key enzyme of pyrimidine
nucleotide synthesis, aspartate transcarbamylase, in
bacteria, which is inhibited by the end product CTP
while being activated by ATP (41).
Our results also suggest that the natural ligand for
the CBS domains of CLC chloride channels is ATP, and
that a mutation in CLC2 (G715E) associated with idio-
pathic generalized epilepsy (6), and a mutation
(G826D) equivalent to one in CLC1 that causes con-
genital myotonia (5), both lead to a severe defect in ATP
binding. While our work was in progress, Vanoye and
George (42) reported, using patch clamp analysis, that
human CLC4 channels only supported a chloride cur-
rent when incubated on the cytoplasmic side with ATP
or a nonhydrolyzable analogue. The CBS domain pairs
of the CLC family are predicted to lie on the cytoplas-
mic side of the membrane. Our results and those of
Vanoye and George suggest that binding of ATP to the
CBS domains of the CLC chloride channels is necessary
before the channels will open.
We therefore propose that, in most cases, tandem
pairs of CBS domains form sensors of cellular energy
status that act by binding AMP and/or ATP. An excep-
tion to this appears to be cystathionine β-synthase
itself, which catalyzes the first step in cysteine synthe-
sis and is allosterically activated by SAM. Its substrate,
homocysteine, is an intermediate in the “activated
methyl cycle” in which SAM (an important donor of
methyl groups during biosynthesis) is regenerated
from S-adenosyl homocysteine. A low activity of cys-
tathionine β-synthase would promote recycling of
homocysteine into SAM, whereas activation of the
enzyme by high concentrations of SAM would favor
removal of homocysteine from the cycle and its con-
version to cysteine instead. Intriguingly, point muta-
tions in the CBS domains of cystathionine β-synthase,
or premature termination or proteolysis that removes
them, result in enzyme that no longer responds to SAM
(2, 43, 44). Kraus and coworkers (33) provided evidence
that the CBS domains form an autoinhibitory domain
whose effect is relieved by SAM binding, which is con-
sistent with the idea that the CBS domains might rep-
resent the binding site for SAM, although this had not
been directly demonstrated. Our present results now
provide strong support for this hypothesis, since the
isolated CBS domains bound one molecule of SAM
with a Kd of 34 µM, while the D444N mutation
increased this to approximately 500 µM (Figure 7).
These results are consistent with previous estimates of
SAM binding to the full-length enzyme of around 15
µM (33), and with results showing that WT cystathio-
nine β-synthase was activated by SAM with a half-max-
imal effect at 7 µM, while in the D444N mutant this
was increased to 460 µM (45). The pathogenic effect of
the D444N mutation might also be due in part to a
reduced expression of the protein (45).
In the case of cystathionine β-synthase, the CBS
domains appear to have been adapted to bind not an
adenine nucleotide, but a related adenosine-contain-
ing compound, SAM. In fact the second CBS domain
in cystathionine β-synthase is rather poorly conserved
(ref. 1; see also the PFAM database, entry no. PF00571,
ref. 46). In addition, a truncation that removes the 
N-terminal 70 residues of cystathionine β-synthase,
which contains the heme-binding region, results in
enzyme that retains 20% of WT activity but is no
longer activated by SAM (47). One possibility is that
the CBS domains of cystathionine β-synthase bind the
adenosyl moiety of SAM, whereas the N-terminal
heme domain is involved in binding of the methionine
moiety, which is not present in ligands that bind to
other CBS domain pairs.
Although our present results provide strong support
for the idea that the CBS domains of the γ subunits of
AMPK provide the allosteric binding sites for AMP and
ATP, a number of puzzling findings remain to be
addressed in future studies. Firstly, the A0.5 values for
activation of WT and mutant versions of the α1β1γ2
complex by AMP were generally around tenfold lower
than the B0.5 values for binding of AMP to the equiva-
lent CBS1-4 constructs. Secondly, the B0.5 for binding
of AMP to the WT CBS1-4 constructs was different for
the three γ subunit isoforms (γ1, 20 µM; γ2, 53 µM; γ3,
125 µM), although the recombinant α1β1γ1, α1β1γ2,
and α1β1γ3 complexes were all activated by similar,
lower concentrations of AMP (A0.5 = 2–13 µM) and dif-
fered instead in their degree of stimulation by AMP
(Figure 4b), in agreement with previous results
obtained with native complexes prepared by immuno-
precipitation (28). Another unexpected finding was
that the CBS domains of γ2 contain two binding sites
for both AMP and ATP. There is an interesting parallel
here with the regulatory subunits of cAMP-dependent
protein kinase, which contain two tandem binding
sites for cAMP, although these are not related to CBS
domains. A current model for activation of cAMP-
dependent protein kinase is that cAMP binds initially
to the C-terminal site (site B), and only then does site A
become accessible, although it is binding to site A that
causes activation (48). Further work is required to
determine whether a similar mechanism operates in the
case of AMPK. The finding that mutations in CBS1
(R302Q), CBS2 (H383R and T400N), and CBS4
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(R531G) all affect AMP activation (Figure 4a) suggests
that AMP must bind to both sites for activation to
occur. However, a sigmoidal activation of AMPK by
AMP (which might be expected if occupancy of both
binding sites were necessary for activation) has not
been reported to our knowledge.
Another puzzling finding is that, although the Sac-
charomyces cerevisiae homologues of the AMPK γ sub-
units (Snf4p) and cystathionine β-synthase both con-
tain CBS domains in the same position as their human
counterparts, they have not been found to be activated
by AMP (38) or SAM (49, 50), respectively.
Finally, one interesting feature of the pathogenic
mutations in CBS domains is that they tend to occur
in equivalent positions. Thus, the R302Q, H383R,
and R531G mutations in CBS1, CBS2, and CBS4 of γ2
all align (plus or minus one residue) with the D444N
mutation in cystathionine β-synthase and with the
R200Q mutation in CBS1 of the γ3 isoform of pig
AMPK (13). Similarly, the T400N mutation in CBS2
of γ2 aligns (plus or minus one residue) with the
R224P mutation in CBS2 of IMPDH1. These “hot
spots” for pathogenic mutations are likely to be
directly involved in binding of the adenosine-con-
taining ligand. A model for the N-terminal domain
pair in the γ2 subunit of AMPK, based on the atomic
coordinates of a bacterial IMPDH (34), is shown in
Figure 8. Two four-stranded β sheets form a deep
hydrophobic cleft between the two domains that is of
suitable dimensions to accommodate an adenosine
moiety. Many of the residues that are mutated in dis-
ease states have basic, positively charged side chains
(e.g., Arg302 and His383 in γ2, and Arg224 in
IMPDH2, which aligns with His401 in γ2) and are pre-
dicted to lie around the mouth of this cleft (Figure 8).
In the CBS domain pairs that bind AMP and/or ATP,
these residues form a positively charged patch at the
mouth of the cleft, which is likely to bind the α phos-
phate moiety of adenine nucleotides. Other residues
that are mutated (Thr400 in γ2, and Gly828 in CLC2,
which aligns with Tyr397 in γ2) are predicted to lie
within the cleft itself, where they may form interac-
tions with the ribose or adenine moieties. Another
notable feature is that the basic residues that form the
basic, positively charged patch at the mouth of the
cleft in γ2 are either uncharged or acidic in cystathio-
nine β-synthase. The D444N mutation in the latter
protein would neutralize a negative charge that occurs
in the equivalent position to Arg302 in γ2. Intrigu-
ingly, the ligand for cystathionine β-synthase, i.e.,
SAM, has a positively charged sulfur atom in approx-
imately the same position as the negatively charged
phosphate of AMP, and it is likely that Asp444 forms
an electrostatic interaction with this sulfur atom.
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